Mass screening for early detection of hepatocellular carcinoma by setting a high-risk population with α-fetoprotein and its glycoforms

Hepatology Research

Volumn 9, Issue 1, 1997, Pages 9-19

  Rimal, N ^a   Ikeda, S ^a   Taketa, K ^a   Kariya, T ^b  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Okayama Health Foundation   (Japan)

Author keywords

AFP glycoforms; AST; Cost effectiveness analysis; HCC; Mass screening; ZTT

Indexed keywords

AGGLUTININ; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; PHYTOHEMAGGLUTININ; ZINC SULFATE;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; COST; EARLY DIAGNOSIS; ECHOGRAPHY; FEMALE; HIGH RISK POPULATION; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL; TURBIDITY;

EID: 0031452047     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(97)00082-x     Document Type: Article

References (42)

1. Parkin DM, Stjernsward J, Muir CS. Estimates of the worldwide frequency of twelve major cancers. Bull Who 1984;62:163-82.
2. London WT. Primary hepatocellular carcinoma-etiology, pathogenesis, and prevention. Human Pathol 1981;12:1085-97.
3. Health and Welfare Statistics Association. National Public Health, its trend (in Japanese). Koseino-Shihyo 1996;43:51-53.
4. Fukumoto S, Obata H, Ikeda S. Liver cancer detected by mass survey and its prognosis (in Japanese). J Gastroenterol Mass Surv 1989;85:71-7.
5. Tang ZY, Yu YG, Zhou XD, et al. Subclinical hepatocellular carcinoma: an analysis of 391 patients. J Surg Oncol 1993;(Suppl) 3:55-8.
6. Ideguchi S, Karai I, Matsuda S, et al. The problems of mass survey for hepatocellular carcinoma from abdominal ultrasonographic mass examination (in Japanese). J Gastroenterol Mass Surv 1995;112:388-92.
7. Segawa K, Kato T, Niwa Y, et al. Problems and measures on the screening of abdominal diseases by ultrasonogram: a study in the subjects of automated multiphasic testings and services (in Japanese). J Gastroenterol Mass Surv 1995;113:493-9.
8. Johnson PJ, Melia WM, Palmer MK, Portmann B, Williams R. Relationship between serum α-fetoprotein, cirrhosis and survival in hepatocellular carcinoma. Br J Cancer 1981;44:502-5.
9. Colombo M. Hepatocellular carcinoma in cirrhotics. Semin Liver Dis 1993;13:374-83.
10. Omata M, Takano S. Occurrence of hepatocellular carcinoma in chronic viral hepatitis. Cancer Chemother Pharmacol 1994;(Suppl) 33:S153-4.
11. Bloomer JR, Waldmann TA, McIntire KR, et al. α-fetoprotein in non-neoplastic hepatic disorders, J Am Med Assoc 1975;233:38-41.
12. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986;6:729-38.
13. Lok ASF, Lai CL. α-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989;9:110-5.
14. Fujiyama S, Morishita T, Hashiguchi O, et al. Plasma abnormal prothrombin (des-γ-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988;61:1621-8.
15. Liebman HA, Furie BC, Tong MJ, et al. Des-γ-carboxy (abnormal) prothrombin as a serurr marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-31.
16. Tsai SL, Huang GT, Yang PM, et al. Plasma des-γ-carboxy prothrombin in the early stage of hepatocellular carcinoma, Hepatology 1990;11:481-7.
17. Breborowicz J, Mackiewiz A, Breborowicz D. Micro-heterogenicity of α-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis. Scand J Immunol 1981;14:15-20.
18. Taketa K, Sekiya C, Namiki M, et al. Lectin-reactive profiles of α-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990;99:508-18.
19. Du MQ, Hutchinson WL, Johnson PJ, et al. Differential alpha-fetoprotein lectin binding in hepatocellular carcinoma: diagnostic utility at low serum levels. Cancer 1991;67:467-80.
20. Taketa K, Ichikawa E, Taga H, et al. Antibody-affinity blotting, a sensitive technique for the detection of α-fetoprotein separated by lectin affinity electrophoresis in agarose gels. Electrophoresis 1985;6:492-7.
21. Nakashima T, Okuda K, Kojiro M, et al. Pathology of hepatocellular carcinoma in Japan. 232 consecutive cases autopsied in 10 years. Cancer 1983;51:863-77.
22. Tsukuma H, Hiyama T. Tamnaka S, et al. Risk factor for hepatocellular carcinoma among patients with chronic liver diseases. N Engl J Med 1993;328:1797 801.
23. Shimokawa Y, Okuda K, Kubo Y. Serum glutamic oxaloacetic transaminase/glutamic pyruvic transaminase ratios in hepatocellular carcinoma. Cancer 1977;40:319-24.
24. Miyake S. The mechanism of the release of hepatic enzymes in various liver diseases. l. Alterations in cytoplasmic and mitochondrial enzyme activities in serum. Acta Med Okayama 1979;33(4):287-304.
25. Sakugawa H, Kuniyoshi T, Katsunari A, et al. A usefulness of ZTT value on the screening of hepatic diseases-clinical evaluation in cases of liver cirrhosis with normal value of transaminase (in Japanese). J Gastroenterol Mass Surv 1990;88:71-5.
26. Taketa K., Liu M, Sekiya C, et al. Increased α-fetoprotein-L3 and -P4 as predictors of preclinical hepatocellular carcinomas. J Tumor Marker Oncol 1994;9:69-75.
27. Bismuth H, Chiche L, Adam R, et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;2:145-51.
28. Rogiers X, Knoefel WT, Malago M, et al. Liver transplantation for hepatocellular carcinoma. Dig Surg 1995;12:61-4.
29. Mcpeake JR, O'Grady JG, Portmann B, et al. Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. J Hepatol 1993;18:226-34.
30. Liver cancer study group of Japan. Survey and follow-up study of primary liver cancer in Japan. Acta Hepatol Jpn 1997;38(5):35-42.
31. Mihara S, Tamanaga M, Narimatsu R, et al. Hepatocellular carcinoma detected by ultrasonic mass survey-A study on the methodology and effectiveness of mass survey for liver cancer (in Japanese). J Gastroenterol Mass Surv 1987;76:80-7.
32. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
33. Kajikawa T, Katahira U, Ohio M, et al. Epidemiological aspects of cases with positive HCV antibody and clinical features of hepatocellular carcinoma with positive HCV antibody based on mass survey in a rural area of Chiba Prefecture. Acta Hepatol Jpn 1996;37:13-8.
34. Yoshida T, Ishiki K, Okuno T, et al. Studies of hepatitis C virus antibody for workers with liver dysfunction (in Japanese). J Hiroshima Med Assoc 1992;45:1253-60.
35. Taketa K, Endo Y, Sekiya C, et al. A collaborative study for the evaluation of lectin-reactive α-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-23.
36. Taketa K, Ikeda S, Omori M. Tumor marker of hepatocellular carcinoma (AFP) (in Japanese). J Clin Sci 1996;32(10):1247-53.
37. Ikeda S, Kobatake T, Umekawa Y, et al. Mass survey for liver disease in district inhabitants (II)-An effective method to detect the primary liver cancer (in Japanese). J Gastroenterol Mass Surv 1988;81:65-71.
38. Mihara S, Tamanaga M, Narimatsu R, Nagano K, Koba H, et al. Hepatocellular carcinoma detected by ultrasonic mass survey-A study on the methodology and effectiveness of mass survey for liver cancer (in Japanese). J Gastroenterol Mass Surv 1987;76:80-7.
39. Shiraki K, Takase K, Tameda Y, et al. A clinical study of lectin-reactive α-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995;22:802-7.
40. Takayasu K, Moriyama N, Muramatsu Y, et al. The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients. Am J Reprod 1990;155:49-54.
41. Curati WL, Halevy A, Gibson RN, et al. Ultrasound, CT, and MRI comparison in primary and secondary tumors of the liver. Gastrointest Radiol 1988;13:123-8.
42. Saito A, Takasaki K, Nakagawa M, et al. Angio-echo method under intravascular carbon dioxide gas injection for liver tumor (in Japanese). Kan-Tan-Sui 1987;15:1129-32.